Efficacy News and Research

RSS

Researchers use network-based approach to examine the impact of policies and vaccination strategies

Predicting the spread of COVID-19 using standard statistical models has its challenges, which is why two Iowa State University researchers developed a network-based approach to look at the impact of specific policies and vaccination strategies throughout the many stages of the pandemic.

6 Jan 2021

Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection

As a part of the COMMUNITY (COVID-19 Immunity) study, researchers from Sweden reveal long-lasting IgG neutralizing antibody response against spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the vast majority of convalescent individuals – even after asymptomatic or mild infection. Their results are currently available on medRxiv* preprint server.

6 Jan 2021

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the U.S. Food and Drug Administration for its development as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) - a rare disease for which there is no FDA-approved first-line therapy.

6 Jan 2021

Researchers receive £230,000 to develop world's first smart vaccine device

Researchers at Swansea University have received £230,000 to develop the world's first smart vaccine device that will both deliver the COVID-19 vaccine and measure its efficacy through monitoring the body's associated response.

6 Jan 2021

NIAID set to conduct large monoclonal SARS-CoV-2 antibody clinical trial

A large clinical trial, known as the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-2), is set to take place, which aims to test monoclonal antibody efficacy and safety in people who have mild or moderate COVID-19.

6 Jan 2021

Disulfide-reducing agents demonstrate potential antiviral activity against SARS-CoV-2

Researchers recently demonstrated that chemical agents capable of reducing disulfide (S-S) bonds can be potentially used as antiviral drugs against SARS-CoV-2, the causative pathogen of COVID-19.

6 Jan 2021

Novel drug may help treat osteoporosis, shows study

A novel form of a drug used to treat osteoporosis that comes with the potential for fewer side effects may provide a new option for patients.

6 Jan 2021

New mathematical model proposes optimal treatment strategies for COVID-19

Getting control of COVID-19 will take more than widespread vaccination; it will also require a better understanding of why the disease causes no apparent symptoms in some people but leads to rapid multi-organ failure and death in others, as well as better insight into what treatments work best and for which patients.

5 Jan 2021

Researchers identify natural products with potential to disrupt viral spread

Researchers at Scripps Institution of Oceanography and Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California San Diego have broken down the genomic and life history traits of three classes of viruses that have caused endemic and global pandemics in the past and identify natural products - compounds produced in nature - with the potential to disrupt their spread.

5 Jan 2021

COVID-19 vaccination in UK may not lead to relaxation of control measures

Researchers have warned that early relaxation of coronavirus disease 2019 (COVID-19) control measures in the UK could lead to pronounced waves of further infection with the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Jan 2021

Mid-term clinical trial results of two cell therapies for critical limb ischemia show similar outcomes

Mid-term results of the first clinical trial designed specifically to evaluate the safety and effectiveness of two cell therapies that are showing early promise in treating angiitis-induced critical limb ischemia were released today in STEM CELLS Translational Medicine.

5 Jan 2021

Cellid, IVI sign research service contract to evaluate immunogenicity of COVID-19 vaccine

Cellid and the International Vaccine Institute have exchanged a collaborative research agreement to analyze the immunogenicity of the COVID-19 vaccine "AdCLD-CoV19".

5 Jan 2021

Repeated ketamine infusions may be a promising treatment for PTSD patients

Repeated intravenous (IV) ketamine infusions significantly reduce symptom severity in individuals with chronic post-traumatic stress disorder (PTSD) and the improvement is rapid and maintained for several weeks afterwards, according to a study conducted by researchers from the Icahn School of Medicine at Mount Sinai.

5 Jan 2021

Replacing the RNA strand with DNA may enhance efficacy of ASO-based drugs

Antisense oligonucleotides (ASO) hold great promise for pharmacotherapy. Now, researchers at Tokyo Medical and Dental University (TMDU) and Ionis Pharmaceuticals, advancing their earlier work on a heteroduplex oligonucleotide (HDO) model, have demonstrated augmentation of ASO-based drugs by replacing the RNA strand with DNA.

5 Jan 2021

Novel endoscopic technique improves detection of upper GI tract tumors

Recently there have been significant advances on several fronts in the ongoing war against cancer of the alimentary tract.

5 Jan 2021

Researchers develop immunity monitoring to determine the efficacy of COVID-19 vaccine

As the COVID-19 vaccine becomes available to the public, immunity monitoring will play an important role in determining whether the vaccine is effective for an individual, and for how long.

5 Jan 2021

Researchers discover protein crucial to T cell metabolism and anti-tumor immune response

Researchers at The University of Texas MD Anderson Cancer Center have discovered that a protein called NF-kappa B-inducing kinase (NIK) is essential for the shift in metabolic activity that occurs with T cell activation, making it a critical factor in regulating the anti-tumor immune response.

4 Jan 2021

Efficacy News and Research

Researchers use network-based approach to examine the impact of policies and vaccination strategies

Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

Researchers receive £230,000 to develop world's first smart vaccine device

NIAID set to conduct large monoclonal SARS-CoV-2 antibody clinical trial

Disulfide-reducing agents demonstrate potential antiviral activity against SARS-CoV-2

Novel drug may help treat osteoporosis, shows study

New mathematical model proposes optimal treatment strategies for COVID-19

Researchers identify natural products with potential to disrupt viral spread

COVID-19 vaccination in UK may not lead to relaxation of control measures

Mid-term clinical trial results of two cell therapies for critical limb ischemia show similar outcomes

Cellid, IVI sign research service contract to evaluate immunogenicity of COVID-19 vaccine

Repeated ketamine infusions may be a promising treatment for PTSD patients

Replacing the RNA strand with DNA may enhance efficacy of ASO-based drugs

Novel endoscopic technique improves detection of upper GI tract tumors

Researchers develop immunity monitoring to determine the efficacy of COVID-19 vaccine

Researchers discover protein crucial to T cell metabolism and anti-tumor immune response

Researchers develop α-emitting cancer therapy using a novel drug targeting LAT1

Biologist receives NIH grant to build software tools to predict cancer drug efficacy

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News